**Enterobacteriaceae Isolated from the River Danube: Antibiotic Resistances, with a Focus on the Presence of ESBL and Carbapenemases**

Clemens Kittinger¹, Michaela Lipp¹, Bettina Folli¹, Alexander Kirschner²-³, Rita Baumert¹, Herbert Galler¹, Andrea J. Grisold¹, Josefa Luxner¹, Melanie Weissenbacher¹, Andreas H. Farnleitner³-⁴, Gernot Zarfel¹*

¹ Institute of Hygiene, Microbiology and Environmental Medicine, Medical University Graz, Graz, Austria, ² Institute for Hygiene and Applied Immunology, Water Hygiene, Medical University of Vienna, Vienna, Austria, ³ Interuniversity Cooperation Centre for Water and Health, ⁴ Institute of Chemical Engineering, Research Group Environmental Microbiology and Molecular Ecology, Vienna University of Technology, Vienna, Austria

* gernot.zarfel@medunigraz.at

**Abstract**

In a clinical setting it seems to be normal these days that a relevant proportion or even the majority of different bacterial species has already one or more acquired antibiotic resistances. Unfortunately, the overuse of antibiotics for livestock breeding and medicine has also altered the wild-type resistance profiles of many bacterial species in different environmental settings. As a matter of fact, getting in contact with resistant bacteria is no longer restricted to hospitals. Beside food and food production, the aquatic environment might also play an important role as reservoir and carrier. The aim of this study was the assessment of the resistance patterns of *Escherichia coli* and *Klebsiella* spp. out of surface water without prior enrichment and under non-selective culture conditions (for antibiotic resistance). During Joint Danube Survey 3 (2013), water samples were taken over the total course of the River Danube. Resistance testing was performed for 21 different antibiotics. Samples were additionally screened for ESBL or carbapenemase harboring *Enterobacteriaceae*. 39% of all isolated *Escherichia coli* and 15% of all *Klebsiella* spp. from the river Danube had at least one acquired resistance. Resistance was found against all tested antibiotics except tigecycline. Taking a look on the whole stretch of the River Danube the proportion of multiresistances did not differ significantly. In total, 35 ESBL harboring *Enterobacteriaceae*, 17 *Escherichia coli*, 13 *Klebsiella pneumoniae* and five *Enterobacter* spp. were isolated. One *Klebsiella pneumoniae* harboring NMD-1 carbapenemases and two *Enterobacteriaceae* with KPC-2 could be identified. Human generated antibiotic resistance is very common in *E. coli* and *Klebsiella* spp. in the River Danube. Even isolates with resistance patterns normally associated with intensive care units are present.
Introduction

We are currently observing the spread of a rising number of anthropogenic antibiotic resistant bacteria (ARB) outside the clinical setting. This is an alarming trend, contributing to the postulated decline of the antibiotic era [1–3]. Especially surface waters seem to play a key role in this spread, as they serve both as habitats and as transport systems for microorganisms [4]. Contrary to clinical settings, where the distribution of resistant bacteria is well-documented [3,5], distribution and evidence of non-wild-type resistant pathogens in the environment are hardly based on qualitative data.

Antibiotics and ARB stem from many different sources like hospital effluents, communities, industry and farming and are flushed into surface waters. This leads to an emerging number of ARB in the environment [6–8]. The ability of resistant bacteria to survive in the aquatic environment and the transfer of resistance genes are not clearly understood. Besides genetic background of the strains and mobility of resistance genes the presence of antibiotics, their degradation products or other substances i.e. metals can influence the stability of the resistance [4,6,7,9]. Antibiotic resistant gram negative bacilli (e.g. Enterobacteriaceae, Pseudomonadales) are favored, as many species are native inhabitants of water environments and they are capable of high trans-species genetic exchanges [4,10]. So today surface waters may not only serve as reservoirs for resistance genes but also as a "market place" where susceptible strains (especially in the presence of antibiotics from waste water) can acquire new resistances [6–8,11].

Worldwide research document the occurrence and increasing presence of nearly all clinically relevant resistance mechanisms in the Enterobacteriaceae family, in all kinds of surface waters from waste to drinking water, in rivers, lakes and in the ocean [12–16].

Especially extended spectrum beta-lactamases (ESBL) producing bacteria have become omnipresent in the last decade. They emerge within clinical settings, human communities and animals (wild life, companion animals and livestock) [17,18]. One reason for the increase of ESBL within population and in animals is the overuse of antimicrobials in veterinary medicine. This leads to the occurrence of ARB in the animals itself and a contamination of the foodstuff of animal origin. The spread of the ARB loaded manure then contaminates soil or surface waters [19,20].

The aim of the study was to evaluate the resistance profiles of Escherichia coli and Klebsiella spp. isolated at selected sites along the whole course of the River Danube. We took the opportunity of the Joint Danube Survey 3 (JDS3), the world’s biggest river research expedition of its kind in 2013, to analyze samples originating from different sampling points along the whole length of the River Danube. The isolates were collected without any antibiotic pressures or pre-enrichment to provide a mostly unbiased picture of the antibiotic resistance of these clinically highly important micro-organisms in the River Danube. A parallel screening on ESBL and carbapenemases producing Enterobacteriaceae in the River Danube water was conducted (Fig 1).

Materials and Methods

Sample collection

All samples were taken from a research vessel during the Joint Danube Survey 2013 (JDS3), organized by the International Commission for the Protection of the Danube River (ICPDR), Vienna. ICPDR has got the permission of all Danube countries for taking samples along the whole Danube River. The ICPDR is a transnational body, which has been established to implement the Danube River Protection Convention. All Danube countries are member states of the ICPDR on the base of the "Convention on Cooperation for the Protection and Sustainable use of the Danube River (Danube River Protection Convention).
Between Aug. 12th and Sep. 26th, 2013, water samples from 68 sampling sites along the River Danube, starting at JDS1 (Böfinger Halde, DE), and from 12 tributaries were collected for microbiological investigation. For each sampling site, samples were taken at three sampling points (left, middle, right), in sterile 1 L glass flasks from 30 cm below the river surface. From each flask duplicate volumes of 45 ml river water were filled into sterile non-toxic 50 ml plastic vials (Techno Plastic Products AG, TPP, Switzerland), containing 5 ml glycerine (final conc. 10% v/v) [21]. The vials were completely mixed by hand and immediately stored at -20°C on board of the cruise ship until analysis in the laboratory. After transfer to the laboratory (beginning of October 2013) the samples were stored at -80°C. Fourteen critical sampling sites, mostly downstream of large cities were chosen for investigation (Table 1). In order to facilitate a better interpretation of the data, the sampling sites were grouped in three stretches: upper-, middle- and down-stretches (Table 1). The upper stretch included JDS2, JDS3, JDS8, JDS10 and JDS22 (1240 river km), represented by 120 E. coli and 136 Klebsella spp. isolates. The middle stretch included JDS28, JDS36, JDS38 and JDS49 (798 river km), represented by 326 E. coli and 88 Klebsella spp. isolates.

The down stretch included JDS57, JDS59, JDS63, JDS67 and JDS68 (808 river km), represented by 183 E. coli and 95 Klebsella spp. isolates.
Each of the defined stretches included two sampling points after waste water treatment plants (WWTP) supporting large cities (Table 1, marked with *), and two sampling sites with not such an influence. In addition starting sampling site at Kehlheim (JDS2) and final sampling site at the River Danube delta St. Gheorge Arm (JDS68) were included also.

### Table 1. Sampling sites.

| SP   | Stretch | Name of SP            | River km | Country |
|------|---------|------------------------|----------|---------|
| JDS2 | upper   | Kelheim, gauging station | 2415     | DE      |
| JDS3 | upper   | Geisling power plant   | 2354     | DE      |
| JDS8 | upper   | Oberloiben             | 2008     | AT      |
| JDS10| upper   | Wildungsmauer (Vienna)*| 1895     | AT      |
| JDS22| upper   | ds Budapest*           | 1632     | HU      |
| JDS28| middle  | us Drava*              | 1384     | HR/RS   |
| JDS36| middle  | ds Tisa / us Sava      | 1200     | RS      |
| JDS38| middle  | us Pančevo (Belgrade)* | 1159     | RS      |
| JDS49| middle  | Pristol / Novo Salo    | 834      | RO/BG   |
| JDS57| down    | ds Ruse*               | 488      | RO/BG   |
| JDS59| down    | ds Arges (Bucharest)*  | 429      | RO/BG   |
| JDS63| down    | Siret                  | 154      | RO      |
| JDS67| down    | Sulina Arm             | 26       | RO      |
| JDS68| down    | St. Gheorge Arm        | 104      | RO      |

JDS3 sampling sites chosen for isolation and their assignment to the upper-, middle- or downstream stretches (SP = sampling point, us = upstream, ds = downstream). Country codes: Germany, DE; Austria, AT; Hungary, HU; Croatia, HR; Serbia, RS; Romania, RO; Bulgaria, BG; * represent sites close to cities.

doi:10.1371/journal.pone.0165820.t001

#### Isolation of bacteria

**Isolation of *E. coli* and *Klebsiella* spp. without resistance selection**

The frozen samples were thawed and plated afterwards in 0.5 ml portions on different (selective) Agars. For each sampling point ten Agar plates of each type were used. For isolation of *E. coli* and *Klebsiella* spp. Endo Agar, Xylose Lysine Desoxychelat Agar (XLD Agar) and Chromocult Coliform Agar (CCA), (all Merck, Austria) were used. Growth conditions were 37 ± 1°C for 18–24 h. All colonies that matched manufacturers’ requirements were transferred to Blood Agar and Endo Agar (24 h, 37°C) to retrieve pure cultures. Species were identified with mass spectrometry VITEK MS (bioMérieux Austria GmbH, Vienna, Austria). These isolates were used for determination of wild-type, resistant and multiresistant proportion of River Danube *E. coli* and *Klebsiella* spp.

**Isolation of ESBL and/or Carbapenemases harboring *Enterobacteriaceae***

The frozen samples were thawed and plated afterwards in 0.5 ml portions on different ChromID Agars. For each sampling point ten Agar plates of each type were used. ChromID ESBL (bioMérieux Austria GmbH, Vienna, Austria) and chromID CARBA (bioMérieux Austria GmbH, Vienna, Austria) were used for screening for ESBL and for carbapenemase-producing *Enterobacteriaceae*. ChromID Agar plates were incubated for 24 h at 37°C. Colonies were assessed as described in the manufacturer’s manual. For pure cultures, colonies growing on chromID Agar were transferred to blood Agar and Endo Agar (24 h, 37°C) and identified with MALDI-TOF Vitek MS. These isolates were not included in the calculation of wild-type, resistant and multiresistant proportion of River Danube *E. coli* and *Klebsiella* spp.
Susceptibility testing

For all identified *Enterobacteriaceae* susceptibility testing was performed as recommended by the European Committee on Antimicrobial Susceptibility testing (EUCAST) [22]. If no EUCAST criteria were available (tetracycline, chloramphenicol and nalidixic acid), testings were carried out according to the Clinical Laboratory Standards Institute (CLSI) [23]. Interpretation of zone diameters was done according to EUCAST or CLSI.

The following antibiotics (21) were used: ampicillin (10 μg), amoxicillin/clavulanic acid (20 μg/10 μg), piperacillin/tazobactam (100 μg/10 μg), cefalexin (30 μg), cefotaxime (30 μg), cefoxitin (30 μg), cefotaxime (5 μg), ceftazidime (10 μg), cefepime (30 μg), imipenem (10 μg), meropenem (10 μg), amikacine (30 μg), gentamicin (10 μg), trimethoprim/sulfamethoxazole (1.25 μg/23.75 μg), ciprofloxacin (5 μg), moxifloxacin (5 μg), tigecyclin (15 μg), tetracycline (30 μg), nalidixic acid (30 μg) chloramphenicol (30 μg) and colistin (10 μg) (Becton Dickinson and Company, Sparks, MD, USA, BD BBL™). Sensi-DiscTM paper discs (BD) were used.

According to EUCAST test criteria for disc diffusion, are only available for *E. coli*. Susceptibility for all other *Enterobacteriaceae* has to be determined with Etest [1]. Etest for tigecyclin was carried out and interpreted according to EUCAST guidelines.

To determine (clinical) resistance to colistin protocols of Gales et al. and Boyen et al. were used [24,25].

*Escherichia coli* ATCC 25922 and *Pseudomonas aeruginosa* ATCC 27853 were used as control strains in all performed tests.

Phenotypically conformation of ESBL and Carbapenemases

The minimum inhibitory concentrations (MICs) for imipenem and meropenem were tested with Etest [1] (bioMérieux Austria GmbH, Vienna, Austria). Expression of carbapenemases was confirmed with modified hodge test [26]. ESBL-positive *E. coli* and *Klebsiella* spp. were confirmed with double disc tests (CLSI) (30 μg ceftazidime, 30 μg cefepime, ceftazidime-clavulanic acid 30/10 μg, cefepime-clavulanic acid 30/10 μg; bioMérieux Austria GmbH, Vienna, Austria). ESBL-positive *Enterobacter* spp. and *Citrobacter* spp. were confirmed with modified double-disc test [27]. *Escherichia coli* ATCC 25922 and *Pseudomonas aeruginosa* ATCC 27853 were used as control strains in all performed tests. Isolates that revealed ESBL and/or Carbapenemase phenotype were tested for their genetic background.

Determination of ESBL and Carbapenemase genes

PCR detection and gene identification were performed for five different β-lactamase gene families, *bla*<sub>CTX-M-1</sub>group, *bla*<sub>CTX-M-2</sub>group, *bla*<sub>CTX-M-9</sub>group, *bla*<sub>TEM</sub>, and *bla*<sub>SHV</sub>. DNA was extracted by boiling of one colony suspended in 50 μl double-deionized water (95°C for 10 min.) After centrifugation for 1 min at 13000 rpm (Centrigrude 5415 R, Eppendorf) supernatant was used for PCR—reaction. PCR and sequencing procedures were performed as described previously [28,29]. Standard PCR protocols and conditions were modified in the following way: initial denaturation at 94°C for 5 min; 35 cycles at 95°C for 30 sec, 52°C for 45 sec, and 72°C for 60 sec; and final incubation for 10 min at 72°C using Taq DNA polymerase and dNTPs from QIAGEN (Hilden, Germany). This was done for all *Enterobacteriaceae* isolates that revealed an ESBL-positive phenotype or were recovered from chromID<sup>®</sup> CARBA plates. Isolates showing resistance to at least one of the tested carbapenems were screened with a Checkpoint MDR 103 kit (Check-Points, Wageningen, The Netherlands) according to the protocol [http://www.check-points.com/support/manuals/](http://www.check-points.com/support/manuals/). Detected carbapenemase genes (*bla*<sub>NDM</sub>, *bla*<sub>KPC</sub>) were characterized by sequencing as described previously [30]. DNA extraction was done as described above for ESBL genes. Standard PCR protocols: initial denaturation at 94°C for 5 min; 35 cycles at 95°C for 30 sec, 52°C for 45 sec, and 72°C for 60 sec; and
final incubation for 10 min at 72°C using Taq DNA polymerase and dNTPs from QIAGEN (Hilden, Germany).

**Multilocus sequence typing (MLST)**

MLST for *E. coli* was done according to the MLST Databases at University of Warwick (http://mlst.warwick.ac.uk/mlst/dbs/Ecoli/) [31] and for *Klebsiella pneumoniae* according to the Institute Pasteur MLST (http://bigsdb.web.pasteur.fr/klebsiella/klebsiella.html) [32,33].

MLST of *Enterobacter cloacae* was done according to the *Enterobacter cloacae* MLST website (http://pubmlst.org/ecloacae) developed by Keith Jolley and sited at the University of Oxford [31]. The development of this site has been funded by the Wellcome Trust.

**Statistical analyses**

Statistical analyses were carried out using R* Version 3.21, a free software environment for statistical computing and graphics (www.r-project.org). Group specific proportions were tested on their equality by a two-sided binomial test. *P* values below 0.05 were assessed as significant.

**Results**

**Resistance pattern of *E. coli* and *Klebsiella* spp.**

In total, 629 *E. coli* and 319 *Klebsiella* spp. (238 *Klebsiella pneumoniae* and 81 *Klebsiella oxytoca*) were isolated under non-selective conditions (according antibiotic resistance). The presence of acquired resistances in the total population was tested for their susceptibility to 21 antibiotics, including clinically relevant antibiotics as well as antibiotics commonly used in farming (e.g. tetracycline).

61.21% (385 isolates) of all *E. coli* isolates and 84.01% (268 isolates) of *Klebsiella* spp. isolates did not show acquired resistance to any of the tested antibiotics (*Klebsiella* spp. are set as naturally resistant to ampicillin). 61 *E. coli* isolates (9.70%) and 7 *Klebsiella* spp. (2.19%) were identified as multiresistant (acquired resistance to three or more antibiotic classes tested). *E. coli* isolates were resistant to up to 14 of 21 tested antibiotics and six of seven tested classes, *Klebsiella* spp. were resistant to up to 12 of 20 antibiotics and five of seven classes. Four isolates (two *E. coli* and two *Klebsiella pneumoniae*) were tested as positive as regards harboring ESBL genes and were analyzed together with ESBL positive isolates from ChromID ESBL and ChromID CARBA Agar plates. All isolates were susceptible to meropenem, imipenem, amikacin and tigecycline. Additionally all *E. coli* isolates were susceptible to piperacillin/tazobactam and colistin, while two *Klebsiella* spp. isolates were resistant to these antibiotics. The most common resistance in both tested species was tetracycline with 24.01% of all isolated *E. coli* and 8.46% of all *Klebsiella* spp. Resistance to ampicillin (21.94%) was second common in *E. coli* isolates, followed by nalidixic acid (10.97%), trimethoprim/sulfamethoxazole (10.17%) and amoxicillin/clavulanic acid (5.88%). All other antibiotics revealed resistance only in less than 5% of the isolates. *Klebsiella* spp. isolates also revealed resistance to tetracycline (8.46%), amoxicillin/clavulanic acid (6.03%) and nalidixic acid (5.02%) with resistance proportions higher than 5% (Table 2).

The upper stretch had the highest proportion of isolates resistant to ampicillin (*E. coli*) with the highest percentage of 33.33% against a single antibiotic in this study. In these isolates resistance to amoxicillin/clavulanic, cephalaxin and cefoxitin was also commonly found. Isolates that revealed resistance to higher generation cephalosporins occurred only sporadically (five or less isolates per stretch), with the one remark that no *E. coli* revealed this resistance in the upstream section. In contrast to the beta-lactam antibiotics, resistance to tetracycline was highest downstream (Table 2).
The proportion of multiresistant *E. coli* did not change significantly (in comparison upper-to-middle stretch: *P* value = 0.9 and middle- to down stretch *P* value = 0.72) over the three stretches with upper- 10.83% (13/120 isolates), middle- 10.12% (33/326 isolates) and down-stream 8.74% (16/183 isolates) respectively (Fig 2).

The low number of multiresistant bacteria in upper- 2.94%, middle- 1.14% and down stretch proportion isolates of *Klebsiella* spp. did not allow for reliable statistic evidence (Fig 3).

Detection and characterization of ESBL harboring *Enterobacteriaceae*

ESBL and carbapenemases were chosen as examples for clinically important resistance mechanisms. The five ESBL positive isolates which were obtained under non-selective condition from the resistance patterns of *E. coli* and *Klebsiella* spp. part were included for detailed analysis. All other isolates except JDS59EB009 that could be obtained from the chromID™ CARBA Agar were isolated from ChromeD™ ESBL.

In total, 35 ESBL harboring *Enterobacteriaceae*, 17 *E. coli*, 13 *Klebsiella pneumoniae* and five *Enterobacter* spp. were isolated. These isolates were obtained from seven of fourteen sampling sites, JDS02 (DE), JDS36 (RS), JDS38 (RS), JDS59 (RO), JDS63 (RO) and JDS68 (RO). In the upper stretch only one isolate (JDS02KL007) could be detected, whereas the majority (22/35) was present in the last four sampling sites (Table 3).

### Table 2. Proportion of antibiotic resistance.

|                | *E. coli* up | *E. coli* middle | *E. coli* down | *E. coli* all | *Klebs. spp* up | *Klebs. spp* middle | *Klebs. spp* down | *Klebs. spp* all |
|----------------|-------------|-----------------|--------------|---------------|-----------------|---------------------|------------------|-----------------|
| **Total**      | 121         | 326             | 183          | 629           | 136             | 88                  | 95               | 319             |
| Ampicillin     | 40 (33.33%) | 66 (20.18%)     | 31 (16.94%)  | 137 (21.78%)  | 136 (100%)      | 88 (100%)           | 95 (100%)        | 319 (100%)      |
| *a* Amox./Clavulanic acid, amox./clavul.;  |
| Cefotaxime     | 6 (5.00%)   | 7 (2.14%)       | 4 (2.19%)    | 17 (2.70%)    | 7 (5.15%)       | 2 (1.47%)           | 1 (1.05%)        | 1 (1.05%)       |
| *b* Piperacillin/tazobactam, pip./taz.;  |
| Ceftazidime    | 0 (0.00%)   | 5 (1.53%)       | 2 (1.09%)    | 7 (1.11%)     | 2 (1.47%)       | 1 (1.14%)           | 1 (1.05%)        | 1 (1.05%)       |
| Cefoxitin      | 6 (5.00%)   | 3 (0.92%)       | 2 (1.09%)    | 11 (1.75%)    | 12 (8.82%)      | 1 (1.14%)           | 0 (0.00%)        | 9 (2.82%)       |
| Gentamicin     | 6 (5.00%)   | 3 (0.92%)       | 5 (1.97%)    | 7 (1.70%)     | 2 (1.47%)       | 0 (0.00%)           | 1 (1.05%)        | 3 (0.94%)       |
| *c* Trimethoprim/sulfamethoxazole, SXT  |
| Cefepine       | 0 (0.00%)   | 0 (0.00%)       | 0 (0.00%)    | 0 (0.00%)     | 0 (0.00%)       | 0 (0.00%)           | 0 (0.00%)        | 0 (0.00%)       |
| Cefotaxime     | 0 (0.00%)   | 0 (0.00%)       | 2 (1.09%)    | 5 (0.79%)     | 2 (1.47%)       | 0 (0.00%)           | 1 (1.05%)        | 4 (1.25%)       |
| Cefuroxime     | 0 (0.00%)   | 2 (0.55%)       | 16 (2.54%)   | 2 (1.47%)     | 1 (1.14%)       | 1 (1.05%)           | 1 (1.05%)        | 2 (0.63%)       |
| Oxacillin      | 0 (0.00%)   | 0 (0.00%)       | 0 (0.00%)    | 0 (0.00%)     | 0 (0.00%)       | 0 (0.00%)           | 0 (0.00%)        | 0 (0.00%)       |
| Meropenem      | 0 (0.00%)   | 0 (0.00%)       | 0 (0.00%)    | 0 (0.00%)     | 0 (0.00%)       | 0 (0.00%)           | 0 (0.00%)        | 0 (0.00%)       |
| Cefalotaxime   | 0 (0.00%)   | 2 (0.61%)       | 2 (0.32%)    | 1 (0.74%)     | 0 (0.00%)       | 1 (1.05%)           | 1 (1.05%)        | 2 (0.63%)       |
| Gentamicin     | 0 (0.00%)   | 4 (1.22%)       | 2 (1.09%)    | 6 (0.95%)     | 1 (0.74%)       | 0 (0.00%)           | 2 (2.11%)        | 3 (0.94%)       |
| Cefotaxime     | 0 (0.00%)   | 0 (0.00%)       | 0 (0.00%)    | 0 (0.00%)     | 0 (0.00%)       | 0 (0.00%)           | 0 (0.00%)        | 0 (0.00%)       |
| Ceftazidime    | 0 (0.00%)   | 0 (0.00%)       | 2 (0.32%)    | 1 (0.74%)     | 0 (0.00%)       | 1 (1.05%)           | 1 (1.05%)        | 2 (0.63%)       |
| Cefradine      | 0 (0.00%)   | 0 (0.00%)       | 0 (0.00%)    | 0 (0.00%)     | 0 (0.00%)       | 0 (0.00%)           | 0 (0.00%)        | 0 (0.00%)       |
| Cefotaxime     | 11 (9.17%)  | 86 (26.91%)     | 52 (28.42%)  | 151 (24.01%)  | 9 (6.62%)       | 3 (3.41%)           | 15 (15.79%)      | 27 (8.46%)      |
| Cefepine       | 0 (0.00%)   | 0 (0.00%)       | 0 (0.00%)    | 0 (0.00%)     | 0 (0.00%)       | 0 (0.00%)           | 0 (0.00%)        | 0 (0.00%)       |
| Cefotaxime     | 14 (11.67%) | 44 (13.46%)     | 11 (6.01%)   | 69 (10.97%)   | 5 (3.68%)       | 3 (3.41%)           | 8 (8.42%)        | 16 (5.02%)      |
| Colistin       | 0 (0.00%)   | 0 (0.00%)       | 0 (0.00%)    | 0 (0.00%)     | 1 (0.74%)       | 1 (1.14%)           | 0 (0.00%)        | 2 (0.63%)       |

Numbers (and proportion) of *E. coli* and *Klebsiella* spp. with resistance to tested antibiotics.

* a amoxicillin/clavulanic acid, amox./clavul.;
* b piperacillin/tazobactam, pip./taz.;
* c trimethoprim/sulfamethoxazole, SXT

doi:10.1371/journal.pone.0165820.t002

The proportion of multiresistant *E. coli* did not change significantly (in comparison upper-to-middle stretch: *P* value = 0.9 and middle- to down stretch *P* value = 0.72) over the three stretches with upper- 10.83% (13/120 isolates), middle- 10.12% (33/326 isolates) and down-stream 8.74% (16/183 isolates) respectively (Fig 2).

The low number of multiresistant bacteria in upper- 2.94%, middle- 1.14% and down stretch 2.11% proportion isolates of *Klebsiella* spp. did not allow for reliable statistic evidence (Fig 3).
Fig 2. Resistance proportion of *E. coli*. Proportion of *E. coli* with wild type susceptibility pattern (green), resistance to antibiotics out of one or two tested classes (resistant, yellow) and resistance to antibiotics out of three or more classes (multiresistant, red) their total presence in the river and in the three stretches.

doi:10.1371/journal.pone.0165820.g002

Fig 3. Resistance proportion of *Klebsiella* spp. Proportion of *Klebsiella* spp. with wild type susceptibility pattern (green), resistance to antibiotics out of one or two tested classes (resistant, yellow) and to antibiotics out of three or more classes (multiresistant, red) their total presence in the river and in the three stretches.

doi:10.1371/journal.pone.0165820.g003
Table 3. ESBL and carbapenemase harboring isolates.

| Isolate No. | Species                  | Source          | ESBL   | Carbapenemase | MDR   | ST  |
|-------------|--------------------------|-----------------|--------|---------------|-------|-----|
| JDS59EC007  | Klebsiella pneumoniae    | JDS59KL001      | R      | R             | R     | ST1 |
| JDS59EC009  | Klebsiella pneumoniae    | JDS59KL002      | R      | R             | R     | ST1 |
| JDS59EC010  | Klebsiella pneumoniae    | JDS59KL003      | R      | R             | R     | ST1 |
| JDS59EC011  | Enterobacter cloacae     | JDS59KL004      | R      | R             | R     | ST1 |
| JDS59EC012  | Enterobacter cloacae     | JDS59KL005      | R      | R             | R     | ST1 |

(Continued)
Table 3. (Continued)

| isolation-Nr | Species                  | source country | source rkm | AM | AMC | TZP | CN  | CXM | FOX | CTX | CAZ | FEP | MEM | IPM | NA  | MXF | CIP | GM  | AN  | TGC | TE  | SXT | C  | CL | TEM | SHV | CTX-M-1 | CTX-M-9 | KPC | NDM | MLST |
|--------------|--------------------------|----------------|------------|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-------|-------|-----|-----|------|
| JDS68EB030   | Enterobacter cancerogenus| RO             | 104        | R  | R   | R   | R   | R   | R   | R   | S   | S   | S   | S   | S   | S   | S   | S   | S   | S   | S   | S   | SHV-2 | n.t.  |     |     |      |
| JDS68KL011   | Klebsiella pneumoniae    | RO             | 104        | R  | R   | S   | R   | R   | R   | R   | S   | S   | S   | R   | R   | S   | S   | R   | S   | S   | S   | S   | SHV-1 | CTX-M-15 | ST 15 |
| JDS68KL012   | Klebsiella pneumoniae    | RO             | 104        | R  | R   | S   | R   | R   | R   | S   | R   | S   | R   | S   | R   | S   | S   | R   | S   | S   | S   | S   | TEM-1 | SHV-1 | CTX-M-15 | ST 15 |
| JDS68KL013   | Klebsiella pneumoniae    | RO             | 104        | R  | S   | S   | R   | R   | S   | R   | S   | S   | S   | R   | S   | S   | S   | R   | S   | S   | S   | S   | TEM-1 | SHV-1 | CTX-M-15 | ST 15 |
| JDS68KL014   | Klebsiella pneumoniae    | RO             | 104        | R  | R   | S   | R   | R   | S   | R   | S   | R   | S   | R   | S   | S   | R   | S   | S   | S   | S   | S   | TEM-1 | SHV-1 | CTX-M-15 | ST 15 |
| JDS68KL015   | Klebsiella pneumoniae    | RO             | 104        | R  | S   | S   | R   | R   | S   | R   | S   | S   | R   | S   | R   | S   | S   | R   | S   | S   | S   | S   | TEM-1 | SHV-1 | CTX-M-15 | ST 15 |

Resistance pattern, encoded beta-lactamas (TEM, SHV CTX-M-1 group, CTX-M-9 group, KPC and NDM) and MLST (if detectable). Antibiotic susceptibility is depicted with S for susceptible and R for resistant (highlighted in orange), classes of antibiotics are marked by different colours. Beta lactam antibiotics (red): Ampicillin, AM; amoxicillin/clavulanic acid, AMC; piperacillin/tazobactam, TZP; ceftalexin, CN; cefuroxime, CXM; cefoxitin, FOX; cefotaxime, CTX; ceftazidime, CAZ; cefepime, FEP; meropenem, MEM and imipenem, IPM; Quinolones (green) moxifloxacin, MXF; ciprofloxacin, CIP and nalidixic acid, NA. Aminoglycosides (blue): gentamicin, GM and amikacine, AN. Tetracycline antibiotics (yellow): tigecycline, TGC and tetracycline, TE. Other classes (white) trimethoprim/sulfamethoxazole, SXT (inhibition of folic acid synthesis); chloramphenicol, C (chloramphenicol) and colistin, CL (polymyxin).

doi:10.1371/journal.pone.0165820.t003
All isolates were not susceptible to ampicillin and cephalosporins, with the exception of cef-tazidime (with 77.14% resistant isolates, including all Enterobacter spp. isolates) and ceftazidime (65.71% resistant isolates). In contrast, the majority of the isolates revealed susceptibility to tazobactam and the cephemycin cefoxitin with only 22.85% and 37.14% resistant isolates.

Co-resistance to sulfamethoxazole/trimethoprim (74.29% of resistant isolates) ciprofloxacin (71.43%), moxifloxacin (68.57%) and gentamicin (62.86%) was very common. Only four of the ten tested non beta-lactam antibiotic displayed less than 50% resistance. Chloramphenicol revealed resistance in 22.86% and amikacine in three (8.57%) isolates, whereas all isolates were susceptible to colistin and tigecycline.

Only five isolates (three E. coli and two Enterobacter spp.) were not classified as multiresistant. Six isolates, including all other Enterobacter spp., two Klebsiella pneumoniae and one E. coli revealed resistances at least to one tested antibiotic out of six represented classes.

Analyzing the genetic background of ESBL resistance, the dominant ESBL family was CTX-M, represented by members of the CTX-M-1 (present in 29 isolates) and CTX-M-9 (one isolate) groups. Genes for CTX-M-15 were found in 20 isolates and these were the most common, also the only ESBL present in E. coli (nine isolates), Klebsiella pneumoniae (ten isolates), and Enterobacter spp. (one isolate). CTX-M-1 (five isolates) occurred in the only Enterobacter asburiae isolate and in four E. coli; CTX-M-3 (two) and CTX-M-27 (one) only occur in E. coli. On the other hand, CTX-M-55 was detected in three Klebsiella pneumoniae, representing one clone isolated at JDS68.

SHV-ESBL was represented by one SHV-2 (JDS68EB030, Enterobacter cancerogenus) and five SHV-12 (two Enterobacter spp., two K. pneumoniae and one E. coli). All K. pneumoniae without a SHV-12 harbored (as a chromosomal feature of this species) also genes for a non-ESBL variant of SHV (SHV-1 or SHV-11).

The isolates JDS38EB037 (Enterobacter cloacae) with TEM-3 was the only isolate with a TEM-ESBL. Non-ESBL TEM-1 was present in 19 isolates.

Multilocus sequence typing (MLST) was performed with all organisms with established MLST protocols in order to be able to compare them more easily to clinical or other environmental isolates.

E. coli MLST revealed twelve different ST’s, ST10, ST48, ST58, ST69, ST131, ST205, ST405, ST617; ST1914, ST3171, ST5688 and ST5689; Klebsiella pneumoniae ST15, ST101, ST395, ST395 and ST2151; and the three Enterobacter cloacae revealed ST145, ST159 and ST505 (first reported in this study).

With one exception all detected MLST STs were only present at one sampling site, whereas the Klebsiella MLST ST15 was present at three sampling sites (JDS02 (DE), JDS38 (RS) and JDS68 (RO)), including the isolates (JDS02KL027 and JDS38KL007) of K. pneumoniae that harbored two different ESBL genes (Table 3).

Detection and characterization of carbapenemase harboring Enterobacteriaceae

Three of the 35 ESBL harboring Enterobacteriaceae were resistant to meropenem and imipenem, and revealed the presence of carbapenemases genes.

JDS38KL007 Klebsiella pneumoniae harbored the gene for NDM-1. In this isolate genes for CTX-M-15, SHV-1 and TEM-1 could also be detected. Out of all isolates in this study this was the one which was resistant to most of the tested antibiotics, leaving only two of them, colistin and tigecycline as susceptible. Klebsiella pneumoniae MLST resulted in ST101. The second carbapenem resistant Klebsiella pneumoniae JDS38KL045 harbored the gene for KPC-2. It also harbored genes encoding CTX-M-15 and a wild type SHV (SHV-11). Susceptibility testing
revealed resistance to all tested antibiotics with the exception of colistin, chloramphenicol, tetracycline and tigecycline. Both *Klebsiella pneumoniae* were isolated at the sampling site upstream Pancevo (Serbia).

JDS9EB009 *Enterobacter asburiae* harbored the KPC-2 carbapenemase, alongside with the genes for the other beta-lactamases CTX-M-1, SHV-12 and TEM-1. It was resistant to all tested beta-lactam antibiotics and the other tested antibiotics with the exception of colistin, moxifloxacin amikacin and tigecycline. It was isolated downstream Arges (RO/BG).

**Discussion**

*E. coli* used to be a handy candidate for treatment with almost every antibiotic. But times have changed and nowadays *E. coli* strains seem to have become super bugs. Furthermore, the fully susceptible and easy to treat *E. coli* wild type could soon become a minority. This change has already taken place in clinical settings in most European countries, as up to 80% of all isolated *E. coli* show already one or more acquired antibiotic resistance. But it has also started to occur in the human community (without direct clinical impact), animals or in (waste) water [5,34–39]. The proportion of resistant *E. coli* in the River Danube also reflects this trend with more than 1/3 of all isolates (in total and in all three stretches respectively). Furthermore 10% of the isolates were already multiresistant affecting clinically relevant antibiotics. Comparing these results to other studies (India, China, Nigeria), the proportion of resistant bacteria is lower [39–42]. Unfortunately there are only a few recent European studies on surface waters available. These studies also show lower resistance rates for *E.coli* (below 50% for river or waste water) [38,43].

The results of this study show that *E. coli* is more affected by the acquisition and stable integration of resistance genes in an aquatic environment than *Klebsiella*. Even if we take into account that ampicillin resistance is intrinsic in *Klebsiella*, this ratio is not changed. Only 23 (3.66%) of all tested *E. coli* revealed exclusive resistance to ampicillin. Hence there are still 1/3 of *E. coli* isolates with other acquired resistances remaining. This difference is also supported by other studies, although there are only a few studies which regard the presence of antibiotic resistance proportion in *Klebsiella* in water environment [17]. In general *E. coli* is more affected by the spread of resistance (e.g. ESBL) in communities than other *Enterobacteriaceae*. In contrast to this *Klebsiella* spp. or *Enterobacter* spp. are more often multiresistant than *E. coli* in clinical settings, especially in intensive care units [44–46].

When comparing neighboring countries to their related River Danube stretches the downstream countries Bulgaria and Rumania have higher resistance rates in clinical isolates of *E. coli* and *Klebsiella pneumoniae* than countries from the upper River Danube regions (e.g. aminoglycosides, fluoroquinolones, 3rd generation cephalosporins and carbapenems) [5]. But this is only reflected in a lower proportion of *Klebsiella pneumoniae* with wild type susceptibility pattern in the downstream stretch and the more frequent isolation of *Enterobacteriaceae* with resistance to 3rd generation cephalosporins.

Under non-selective culture conditions only three sampling sites revealed ESBL positive *E. coli* or *Klebsiella*, representing a proportion of four out of 629 *E. coli* and two out of 319 *Klebsiella*, less than 1% of the isolates. There were also only six out of 14 sampling sites with ESBL positive *Enterobacteriaceae*. The presence of ESBL in the first and the last sampling sites confirms the suspected presence of ESBL over the total course of the River Danube.

The isolated genes represent the most dominant ESBL in Europe. CTX-M-15 has spread wildly in hospital and community settings in the last ten years [39]. Well known *E. coli* host strains for CTX-M enzymes like ST10, ST69, ST131 or ST405 or *Klebsiella pneumoniae* ST15 are present in the Danube water [47–50].
According to the literature the following potential sources, could be assigned to the identified ST-types: ST10 with CTX-M-15 is found in surface water and fish; ST69 with CTX-M-15, ST131 with CTX-M-15 or CTX-M-27, ST405 with CTX-M-15 are found also in surface water, but their primary sources are humans. ST48 with CTX-M-1 is a potential avian pathogen. [51–53]

TEM ESBL was very rare in the Danube isolates. No TEM-52 was detectable; this ESBL is common in human and farm animals but without the dominance of the detected CTX-M and SHV genes. Other studies from Europe report the dominance of CTX-M (including CTX-M-1, CTX-M-3, CTX-M-15, CTX-M-27 and CTX-M-55) and the presence of SHV and the absence of TEM-52 or TEM ESBL in many different surface waters [12,54,55].

Detection of ESBL harboring Enterobacteriaceae has become common in surface water (including drinking water) worldwide [12,16]. Recent reports suggest that at the end of this decade it will be the same for Enterobacteriaceae producing carbapenemases. The occurrence of KPC, OXA-48 and VIM in waste water, rivers and lakes is already documented for Europe [56,57].

The detection of two KPC-2 producers in the River Danube was not totally unexpected, especially at sampling sites where neighboring countries have to deal with high prevalence of carbapenem resistant Enterobacteriaceae in clinical isolates [50,58].

NDM-1 harboring bacteria have been present in the Balkan region since the end of the last decade with several reports from the west and south Balkan. Up to now, these findings were restricted to clinical isolates. A recent study published by Novovic et al. that included also samples from the Danube River collected at the same time as the JDS samples did not find any NDM-1 producer in the environmental water. In our study we were for the first time able to detect this Balkan NDM-1 outside a medical setting [15,58–62]. The detected NDM-1 harboring Klebsiella pneumoniae ST101 is also associated with carbapenem resistant Klebsiella in the Mediterranean region, but this resistance is mediated via KPC-2 and OXA-48 [50,63].

All three carbapenemase producers and most of the ESBL isolates leave only a few therapeutic options. A few years ago the occurrence of this kind of bacteria resulted in alarming case reports [45]. Now they are present in one of Europe’s biggest rivers and it took only less than 1 liter of surface water to isolate them.

**Conclusion**

This study clearly demonstrates the presence of acquired antibiotic resistance in Enterobacteriaceae, in one of Europe’s biggest surface water systems caused by human. It is even more alarming as not only a few isolates, detected under selective conditions, are affected, but in some stretches nearly up to 50% of all isolates show altered resistance. Also the low number of ESBL, which could be only found in half of all the sampling sites, is not due to the lack of emergence but more likely caused by the small sample volume, a known study limitation (lack of space on the JDS3 ships).

The River Danube serves as a reservoir for nearly all clinically important antibiotic resistances in Enterobacteriaceae. Further studies will have to clarify if the proportion of resistant bacteria has reached a stable level or if wild type susceptibility patterns will be in the minority soon.

**Supporting Information**

S1 Table. List of all E. coli isolates and their susceptibility pattern.
(XLSX)

S2 Table. List of all Klebsiella spp. isolates and their susceptibility pattern.
(XLSX)
S3 Table. River kilometers and geographic coordinates of the sampling sites.
(XLSX)

Acknowledgments

The Joint Danube Survey was organized by the International Commission for the Protection of the Danube River (ICPDR). The study was supported by the Austrian Science Fund (FWF), project nr P25817-B22. We further thank Georg Reischer, Stefan Jakwerth and Stoimir Kolarevic for their help in sampling and Michaela Haller for preparing the English manuscript.

The authors declare to have no conflicts of interests and no financial relationships that might lead to a conflict of interests.

Author Contributions

Conceptualization: CK GZ.
Data curation: CK GZ.
Formal analysis: CK GZ JL.
Funding acquisition: AK.
Investigation: ML BF RB JL MW.
Methodology: CK GZ HG AK.
Project administration: CK GZ ML.
Resources: AK AHF AJG.
Validation: CK GZ ML BF RB.
Visualization: CK GZ.
Writing – original draft: CK GZ.
Writing – review & editing: CK GZ AK AHF AJG.

References

1. Viens AM, Littmann J. Is Antimicrobial Resistance a Slowly Emerging Disaster? Public Health Ethics. 2015; 8: 255–265. doi: 10.1093/phe/phv015 PMID: 26566396
2. Livermore DM. Fourteen years in resistance. Int J Antimicrob Agents. 2012; 39: 283–294. doi: 10.1016/j.ijantimicag.2011.12.012 PMID: 22386741
3. Iredell J, Brown J, Tagg K. Antibiotic resistance in Enterobacteriaceae: mechanisms and clinical implications. BMJ. 2016; 352: h6420. doi: 10.1136/bmj.h6420 PMID: 26858245
4. Taylor NG, Verner-Jeffreys DW, Baker-Austin C. Aquatic systems: maintaining, mixing and mobilising antimicrobial resistance? Trends Ecol Evol. 2011; 26: 278–284. doi: 10.1016/j.tree.2011.03.004 PMID: 21458879
5. ECDC. European Centre for Disease Prevention and Control (2014). Antimicrobial resistance surveillance in Europe 2013. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). 2014.
6. Kummerer K. Antibiotics in the aquatic environment—a review—part I. Chemosphere. 2009; 75: 417–434. doi: 10.1016/j.chemosphere.2008.11.086 PMID: 19185900
7. Kummerer K. Antibiotics in the aquatic environment—a review—part II. Chemosphere. 2009; 75: 435–441. doi: 10.1016/j.chemosphere.2008.12.006 PMID: 19178931
8. Bouki C, Venieri D, Dimadopoulos E. Detection and fate of antibiotic resistant bacteria in wastewater treatment plants: a review. Ecotoxicol Environ Saf. 2013; 91: 1–9. doi: 10.1016/j.ecoenv.2013.01.016 PMID: 23414720
9. Baker-Austin C, Wright MS, Stepanauskas R, McArthur JV. Co-selection of antibiotic and metal resistance. Trends Microbiol. 2006; 14: 176–182. doi: 10.1016/j.tim.2006.02.006 PMID: 16537105

10. Davison J. Genetic exchange between bacteria in the environment. Plasmid. 1999; 42: 73–91. doi: 10.1006/plas.1999.1421 PMID: 10489325

11. Rizzo L, Manaia C, Merlin C, Schwartz T, Dagol C, Ploy MC, et al. Urban wastewater treatment plants as hotspots for antibiotic resistant bacteria and genes spread into the environment: a review. Sci Total Environ. 2013; 447: 345–360. doi: 10.1016/j.scitotenv.2013.01.032 PMID: 23396083

12. Zurfluh K, Hachler H, Nuesch-Indenerbinen M, Stephan R. Characteristics of extended-spectrum beta-lactamase- and carbapenemase-producing Enterobacteriaceae Isolates from rivers and lakes in Switzerland. Appl Environ Microbiol. 2013; 79: 3021–3026. doi: 10.1128/AEM.00054-13 PMID: 23455339

13. Schaefer AM, Goldstein JD, Reif JS, Fair PA, Bossart GD. Antibiotic-resistant organisms cultured from Atlantic bottlenose dolphins (Tursiops truncatus) inhabiting estuarine waters of Charleston, SC and Indian River Lagoon, FL. Ecohealth. 2009; 6: 33–41. doi: 10.1007/s10393-009-0221-5 PMID: 19415386

14. Belmonte O, Drouet D, Alba J, Molton MP, Kuli B, Lugagne-Delpon N, et al. Evolution of Enterobacteriaceae resistance to antibiotics in Reunion Island: emergence of extended-spectrum beta-lactamases. Pathol Biol (Paris). 2010; 58: 18–24.

15. Novovic K, Filipic B, Veljovic K, Begovic J, Mirkovic N, Jovicic B. Environmental waters and blaNDM-1 in Belgrade, Serbia: endemicity questioned. Sci Total Environ. 2015; 511: 393–398. doi: 10.1016/j.scitotenv.2014.12.072 PMID: 25569574

16. Zhang H, Zhou Y, Guo S, Chang W. Prevalence and characteristics of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae isolated from rural well water in Taian, China, 2014. Environ Sci Pollut Res Int. 2015; 22: 11488–11492. doi: 10.1007/s11356-015-4387-9 PMID: 25821088

17. Livermore DM, Canton R, Gniadkowski M, Nordmann P, Rossolini GM, Arlet G, et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother. 2007; 59: 165–174. doi: 10.1093/jac/dkl483 PMID: 17158117

18. Carattoli A. Animal reservoirs for extended spectrum beta-lactamase producers. 2008; 14: 117–123.

19. Torneke K, Torren-Edo J, Grave K, Mackay DK. The management of risk arising from the use of antimicrobial agents in veterinary medicine in EU/EEA countries—a review. J Vet Pharmacol Ther. 2015; 38: 519–528. doi: 10.1111/j.vpt.12226 PMID: 25855219

20. Rahube TO, Yost CK. Characterization of a mobile and multiple plasmid isolated from swine manure and its detection in soil after manure application. J Appl Microbiol. 2012; 112: 1123–1133. doi: 10.1111/j.1365-2672.2012.05301.x PMID: 22486928

21. JDS 3. Joint Danube Survey 3. A Comprehensive Analysis of Danube Water Quality. Vienna: ICPDR—International Commission for the Protection of the Danube River; 2015.

22. EUCAST. European Committee on Antimicrobial Susceptibility Testing (EUCAST). 2013. Available: http://www.eucast.org/

23. CLSI, Clinical and Laboratory Standards Institute. Performance Standards for antimicrobial susceptibility testing: 18th informational supplement. CLSI document M100-S18. 2008; Clinical and Laboratory Standards Institute, Wayne, PA.

24. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol. 2001; 39: 183–190. doi: 10.1128/JCM.39.1.183-190.2001 PMID: 11136768

25. Boyen F, Vangroenweghe F, Butaye P, De Graef E, Castryck F, Heylen P, et al. Disk prediffusion is a reliable method for testing colistin susceptibility in porcine E. coli strains. Vet Microbiol. 2010; 144: 359–362. doi: 10.1016/j.vetmic.2010.01.010 PMID: 2172663

26. Lee K, Chong Y, Shin HB, Kim YA, Yong D, Yum JH. Modified Hodge and EDTA-disk synergy tests to screen metallo-beta-lactamase-producing strains of Pseudomonas and Acinetobacter species. Clin Microbiol Infect. 2001; 7: 88–91. PMID: 11298149

27. Pitout JD, Reisbig MD, Venter EC, Church DL, Hanson ND. Modification of the double-disk test for detection of enterobacteriaceae producing extended-spectrum and AmpC beta-lactamases. J Clin Microbiol. 2003; 41: 3933–3935. doi: 10.1128/JCM.41.8.3933-3935.2003 PMID: 12904422

28. Kiratini S, Apisarnthanarak A, Laesripa C, Saifen P. Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health-care-associated infection in Thailand, where the CTX-M family is endemic. Antimicrob Agents Chemother. 2008; 52: 2818–2824. doi: 10.1128/AAC.00171-08 PMID: 18508581

29. Eckert C, Gauthier V, Saladin-Allard M, Hidri N, Verdet C, Ould-Hocine Z, et al. Dissemination of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Paris, France. Antimicrob Agents Chemother. 2004; 48: 1249–1255. doi: 10.1128/AAC.48.4.1249-1255.2004 PMID: 15047527
30. Bradford PA, Bratu S, Urban C, Visalli M, Mariano N, Landman D, et al. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. Clin Infect Dis. 2004; 39: 55–60. doi: 10.1086/421495 PMID: 15206053

31. Jolley KA, Maiden MC. BIGSdb: Scalable analysis of bacterial genome variation at the population level. BMC Bioinformatics. 2010; 11: 595-2105-11-595.

32. Diancourt L, Passet V, Verhoef J, Grimont PA, Brisse S. Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates. J Clin Microbiol. 2005; 43: 4178–4182. doi: 10.1128/JCM.43.8.4178-4182.2005 PMID: 16081970

33. Brisse S, Fevre C, Passet V, Issenhuth-Jeanjean S, Tournebize R, Diancourt L, et al. Virulent clones of Klebsiella pneumoniae: identification and evolutionary scenario based on genomic and phenotypic characterization. PLoS One. 2009; 4: e4982. doi: 10.1371/journal.pone.0004982 PMID: 19319196

34. Paterson DL. Resistance in gram-negative bacteria: enterobacteriaceae. Am J Med. 2006; 119: S20–8; discussion S62-70.

35. Luczkiewicz A, Jankowska K, Fudala-Ksiązek S, Oanczuk-Neyman K. Antibimicrobial resistance of fecal indicators in municipal wastewater treatment plant. Water Res. 2010; 44: 5089–5097. doi: 10.1016/j.watres.2010.08.007 PMID: 20810144

36. Pignato S, Coniglio MA, Faro G, Lefevre M, Weill FX, Giammanco G. Molecular epidemiology of ampicillin resistance in Salmonella spp. and Escherichia coli from wastewater and clinical specimens. Foodborne Pathog Dis. 2010; 7: 945–951. doi: 10.1089/fpd.2009.0504 PMID: 20367333

37. Ewers C, Bethe A, Semmler T, Guenther S, Wieler LH. Extended-spectrum beta-lactamase-producing and AmpC-producing Escherichia coli from livestock and companion animals, and their putative impact on public health: a global perspective. Clin Microbiol Infect. 2012; 18: 646–655. doi: 10.1111/j.1469-0691.2012.03850.x PMID: 22519858

38. Reinthaler FF, Galler H, Feierl G, Haas D, Leitner E, Mascher F, et al. Resistance patterns of Escherichia coli isolated from sewage sludge in comparison with those isolated from human patients in 2000 and 2009. J Water Health. 2013; 11: 13–20. doi: 10.2166/wht.2012.207 PMID: 23428545

39. Poonia S, Singh TS, Tsering DC. Antibiotic susceptibility profile of bacteria isolated from natural sources of water from rural areas of East Sikkim. Indian J Community Med. 2014; 39: 156–160. doi: 10.4103/0970-0218.137152 PMID: 25136156

40. Titilawo Y, Sibanda T, Obi L, Okoh A. Multiple antibiotic resistance indexing of Escherichia coli to identify high-risk sources of faecal contamination of water. Environ Sci Pollut Res Int. 2015; 22: 10969–10980. doi: 10.1007/s11356-014-3887-3 PMID: 25779106

41. Zheng S, Qiu X, Chen B, Yu X, Liu Z, Zhong G, et al. Antibiotics pollution in Jiulong River estuary: source, distribution and bacterial resistance. Chemosphere. 2011; 84: 1677–1685. doi: 10.1016/j.chemosphere.2011.04.076 PMID: 21620433

42. Zhang X, Li Y, Liu B, Wang J, Feng C, Gao M, et al. Prevalence of veterinary antibiotics and antibiotic-resistant Escherichia coli in the surface water of a livestock production region in northern China. PLoS One. 2014; 9: e110102. doi: 10.1371/journal.pone.0110102 PMID: 25372873

43. Blaak H, Lynch G, Italiaander R, Hamidjaja RA, Schets FM, de Roda Husman AM. Multidrug-Resistant and Extended Spectrum Beta-Lactamase-Producing Escherichia coli in Dutch Surface Water and Wastewater. PLoS One. 2015; 10: e0127752. doi: 10.1371/journal.pone.0127752 PMID: 26030904

44. Rice LB. The clinical consequences of antimicrobial resistance. Curr Opin Microbiol. 2009; 12: 476–481. doi: 10.1016/j.mib.2009.08.001 PMID: 19716760

45. Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med. 2012; 18: 263–272. doi: 10.1016/j.molmed.2012.03.003 PMID: 22480775

46. Korzeniewska E, Harnisz M. Extended-spectrum beta-lactamase (ESBL)-positive Enterobacteriaceae in municipal sewage and their emission to the environment. J Environ Manage. 2013; 128: 904–911. doi: 10.1016/j.jenvman.2013.06.051 PMID: 23886578

47. Mathers AJ, Peirano G, Pitout JD. Escherichia coli ST131: The quintessential example of an international multiresistant high-risk clone. Adv Appl Microbiol. 2015; 90: 109–154. doi: 10.1016/bs.aambs.2014.09.002 PMID: 25596031

48. Pietzsch M, Eller C, Wendt C, Holfelder M, Falgenhauer L, Fruth A, et al. Molecular characterisation of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli isolates from hospital and ambulatory patients in Germany. Vet Microbiol. 2015.

49. Reuland EA, Overdevest IT, Al Naiemi N, Kalpoje JS, Rijnsburger MC, Raadsen SA, et al. High prevalence of ESBL-producing Enterobacteriaceae carriage in Dutch community patients with gastrointestinal complaints. Clin Microbiol Infect. 2013; 19: 542–549. doi: 10.1111/j.1469-0691.2012.03947.x PMID: 22757622
50. Markovska R, Stoeva T, Schneider I, Boyanova L, Popova V, Dacheva D, et al. Clonal dissemination of multilocus sequence type ST15 KPC-2-producing Klebsiella pneumoniae in Bulgaria. APMIS. 2015; 123: 887–894. doi: 10.1111/apm.12433 PMID: 26303718

51. Dissanayake DR, Octavia S, Lan R. Population structure and virulence content of avian pathogenic Escherichia coli isolated from outbreaks in Sri Lanka. Vet Microbiol. 2014; 168: 403–412. doi: 10.1016/j.vetmic.2013.11.028 PMID: 24386626

52. Sola-Gines M, Gonzalez-Lopez JJ, Cameron-Veas K, Piedra-Carrasco N, Cerda-Cuellar M, Migura-Garcia L. Houseflies (Musca domestica) as Vectors for Extended-Spectrum beta-Lactamase-Producing Escherichia coli on Spanish Broiler Farms. Appl Environ Microbiol. 2015; 81: 3604–3611. doi: 10.1128/AEM.04522-14 PMID: 25795670

53. Muller A, Stephan R, Nuesch-Inderbinen M. Distribution of virulence factors in ESBL-producing Escherichia coli isolated from the environment, livestock, food and humans. Sci Total Environ. 2016; 541: 667–672. doi: 10.1016/j.scitotenv.2015.09.135 PMID: 26437344

54. Ojer-Usoez E, Gonzalez D, Garcia-Jalon I, Vitas AI. High dissemination of extended-spectrum beta-lactamase-producing Enterobacteriaceae in effluents from wastewater treatment plants. Water Res. 2014; 56: 37–47. doi: 10.1016/j.watres.2014.02.041 PMID: 24651016

55. Zarfel G, Galler H, Feierl G, Haas D, Kittinger C, Leitner E, et al. Comparison of extended-spectrum-beta-lactamase (ESBL) carrying Escherichia coli from sewage sludge and human urinary tract infection. Environ Pollut. 2013; 173: 192–199. doi: 10.1016/j.envpol.2012.09.019 PMID: 23202650

56. Poirel L, Barbosa-Vasconcelos A, Simoes RR, Da Costa PM, Liu W, Nordmann P. Environmental KPC-producing Escherichia coli isolates in Portugal. Antimicrob Agents Chemother. 2012; 56: 1662–1663. doi: 10.1128/AAC.05850-11 PMID: 22203588

57. Galler H, Feierl G, Petternel C, Reinthaler FF, Haas D, Grisold AJ, et al. Emergence of carbapenem-resistant Enterobacteriaceae detected in an Austrian wastewater treatment plant. Clin Microbiol Infect. 2013.

58. Toth A, Damjanova I, Puskas E, Janvari L, Farkas M, Dobak A, et al. Emergence of a colistin-resistant KPC-2-producing Klebsiella pneumoniae ST258 clone in Hungary. Eur J Clin Microbiol Infect Dis. 2010; 29: 765–769. doi: 10.1007/s10096-010-0921-3 PMID: 20401676

59. Zarfel G, Hoenigl M, Wurstl B, Leitner E, Salzer HJ, Valentijn T, et al. Emergence of carbapenem-resistant Enterobacteriaceae in Austria, 2001–2010. Clin Microbiol Infect. 2011; 17: E5–8. doi: 10.1111/j.1469-0691.2011.03659.x PMID: 21939472

60. Mazzariol A, Bosnjak Z, Ballarini P, Budimir A, Bedenic B, Kalenic S, et al. NDM-1-producing Klebsiella pneumoniae, Croatia. Emerg Infect Dis. 2012; 18: 532–534. doi: 10.3201/eid1803.1103890 PMID: 22377049

61. Hammerum AM, Toleman MA, Hansen F, Kristensen B, Lester CH, Walsh TR, et al. Global spread of New Delhi metallo-beta-lactamase 1. Lancet Infect Dis. 2010; 10: 829–830. doi: 10.1016/S1473-3099(10)70276-0 PMID: 21109169

62. Voulgari E, Gartzonika C, Vrioni G, Politi L, Priavali E, Levidiotou-Stefanou S, et al. The Balkan region: NDM-1-producing Klebsiella pneumoniae ST11 clonal strain causing outbreaks in Greece. J Antimicrob Chemother. 2014; 69: 2081–2087. doi: 10.1093/jac/dku105 PMID: 24739146

63. Del Franco M, Paone L, Novati R, Giacomazzi CG, Bagattini M, Galotto C, et al. Molecular epidemiology of carbapenem resistant Enterobacteriaceae in Valle d’Aosta region, Italy, shows the emergence of KPC-2 producing Klebsiella pneumoniae clonal complex 101 (ST101 and ST1789). BMC Microbiol. 2015, 15: 260-015-0597-z.